Cancer Blocker Begins Clinical Trials

07-28-2012 • arclein

when ribosome biogenesis is dysregulated, proteins are overproduced, creating rampant cell growth, a hallmark of cancer; and abnormalities of the nucleolus, the site of ribosome biogenesis, have been used as an indicator of cancer for over 100 years